AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02664922
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.~1 of 2 sedation groups for VT ablation and afib procedures.
Trial: NCT02664922
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 general anesthesia group for VT ablations and afib procedures.
Trial: NCT00100009
Drug: TAC-PF
RxNorm normalized name: PF-06459988
DrugBank: PF-06459988 (DB14768)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00100009
Drug: Triamcinolone Acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04061590
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04061590
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT04061590
Drug: Pemetrexed Disodium
RxNorm normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT01492686
Drug: MCI-186 in open label phase
RxNorm normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients after the double blind phase may receive MCI-186 in 7th until 12th treatment - observation cycles at the patients' will.
Trial: NCT00079638
Drug: Niacin
RxNorm normalized name: Niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00079638
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00079638
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03182140
Drug: Kyleena
RxNorm normalized name: Kyleena
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Kyleena - intrauterine delivery system containing 19.5 mg LNG
Trial: NCT00981747
Drug: Sildenafil and Losartan
RxNorm normalized name: losartan and amlodipine
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil 20mg three times per day and Losartan 25mg two times per day followed by a one month washout prior to next intervention.
Trial: NCT01264354
Drug: Clevudine 30mg
RxNorm normalized name: zinc pyrithione
DrugBank: Clevudine (DB06683)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clevudine 30mg
Trial: NCT01264354
Drug: Clevudine 20mg+Adefovir dipivoxil 10mg
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clevudine 20mg+ Adefovir 10mg
Trial: NCT01264354
Drug: Clevudine 20mg
RxNorm normalized name: zinc pyrithione
DrugBank: Clevudine (DB06683)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clevudine 20mg
Trial: NCT01722162
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02604173
Drug: Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inhaled Budesonide vs. PO Acetazolamide vs. Placebo for prevention of Acute Mountain Sickness
Trial: NCT02604173
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled Budesonide vs. PO Acetazolamide vs. Placebo for prevention of Acute Mountain Sickness
Trial: NCT00691873
Drug: Xolair
RxNorm normalized name: Xolair
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
Trial: NCT04205344
Drug: Bupivacaine 5 mg
RxNorm normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Receive subarachnoid hyperbaric bupivacaine at a dose of 5 mg
Trial: NCT04205344
Drug: Bupivacaine 10 mg
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Receive subarachnoid hyperbaric bupivacaine at a dose of 10 mg
Trial: NCT01131039
Drug: Gemcitabine/Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Gemcitabine: IV, days 1,8, and every 21 days~Bevacizumab: IV, day 1 and every 21 days until disease progression
Trial: NCT01722162
Drug: Levocetirizine
RxNorm normalized name: Levocetirizine
DrugBank: Levocetirizine (DB06282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00105222
Drug: Sodium Nitrite
RxNorm normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00669851
Drug: AI-700
RxNorm normalized name: AI-128
DrugBank: AI-128 (DB05841)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00181649
Drug: Recombinant human prolactin
RxNorm normalized name: prolactin
DrugBank: Prolactin G129R (DB18431)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01172964
Drug: flucytosine
RxNorm normalized name: Flucytosine
DrugBank: Flucytosine (DB01099)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02507843
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Cholecalciferol(100000 IU) will be administered in Vitamin D group monthly for 6 months.
Trial: NCT02102100
Drug: nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In each of 3 test sessions, subjects in each arm will receive a randomized sequence of three intravenous infusions (30 sec each), one hour apart. The infusions will consist of saline, nicotine (.25 mg / 70kg) and nicotine (0.5 mg / 70 kg). The randomized sequence will remain the same between test sessions for a given subject.
Trial: NCT02102100
Drug: menthol
RxNorm normalized name: Menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In each of 3 test sessions, subjects will take 6 inhalations from the study e-cigarette, one inhalation every 15 seconds, of the randomized menthol condition for that test session ust prior to each intravenous infusion. The menthol conditions are: 3.2% menthol, 0.5% menthol and tobacco-flavor only (0.0% menthol)
Trial: NCT02939482
Drug: Triamcinolone Acetonide and normal saline solution
RxNorm normalized name: NS-2359
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg/2 ml Triamcinolone Acetonide and 18 ml normal saline solution
Trial: NCT00248144
Drug: Famciclovir
RxNorm normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00648505
Drug: Glipizide and Metformin HCl Tablets 5 mg/500 mg
RxNorm normalized name: glipizide / metformin hydrochloride Oral Tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5/500mg, single dose fed
Trial: NCT02798211
Drug: Secukinumab 300 mg
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150 mg x 2 s.c. injection
Trial: NCT02798211
Drug: Secukinumab 150 mg
RxNorm normalized name: secukinumab 150 MG/ML
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150 mg s.c. injection
Trial: NCT03126864
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/m2 administered by vein on Days -5 to -3.
Trial: NCT02612285
Drug: SNX-5422
RxNorm normalized name: SNX-5422
DrugBank: SNX-5422 (DB06070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule(s) dosed every other day for 21 days (total 11 doses) out of a 28-day treatment cycle
Trial: NCT03114657
Drug: Crenezumab
RxNorm normalized name: Crenezumab
DrugBank: Crenezumab (DB11959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
Trial: NCT02163616
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 800 mcg of sublingual misoprostol
Trial: NCT00329641
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00329641
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00329641
Drug: sorafenib tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01036659
Drug: ecallantide - Kallikrein inhibitor that blocks the production of bradykinin
RxNorm normalized name: ecallantide Injectable Product
DrugBank: Ecallantide (DB05311)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous dose of 30mg of ecallantide or placebo (three 10 mg SC injections at three different sites ((arms, legs, abdomen). Injections are not to be administered at the attack location.
Trial: NCT00104442
Drug: Rivastigmine
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04453930
Drug: Platinum
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin： Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/5/6).~Cisplatin： Cisplatin intravenous infusion was administered at a dose of 30 milligrams per square meter (mg/m\^2) on Day 1，8 of every 21-day cycle during the induction phase (Cycles 1-4/5/6).
Trial: NCT04524585
Drug: Neuromuscular blockade
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisatracurium will be infused to achieve esophageal pressure targets and maintain a Riker Sedation-Agitation Scale (SAS) score of 1-2. Additional boluses of cisatracurium will be delivered as required and adjustment of continuous infusion rate. After establishing a sedation and NMB strategy at which safe spontaneous breathing is achieved, we will seek to determine whether these targets can be maintained over a 24-hour period.
Trial: NCT04453930
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan intravenous infusion was administered at a dose of 65 milligrams per square meter (mg/m\^2) on Day 1，8 of every 21-day cycle during the induction phase (Cycles 1-4/5/6).
Trial: NCT04453930
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib was administered at a dose of 250 mg during the maintenance phase.
Trial: NCT03375515
Drug: Hydromorphone
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. For opioid-intolerant patients: continuous infusion of hydromorphone 0 mg per hour, and a demand dose of 0.5 mg with a lockout interval of 15 minutes.~2. For opioid-tolerant patients: basal rate 0 mg per hour, and a demand dose of 10% of the hydromorphone dose equivalent to the total opioid taken in the previous 24 hrs with a lockout interval of 15 minutes.
Trial: NCT00396877
Drug: Clopidogrel (SR25990)
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Form: reconstituted solution using Clopidogrel powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight
Trial: NCT03453281
Drug: Aflibercept Injection [Eylea]
RxNorm normalized name: aflibercept Injection [Eylea]
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal Aflibercept injections were performed by vitreoretinal consultant at the place of study.
Trial: NCT01546038
Drug: PF-04449913
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04449913 administered orally and continuously for 28-days.
Trial: NCT01546038
Drug: Low dose ARA-C (LDAC)
RxNorm normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
Trial: NCT01546038
Drug: PF-04449913
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04449913 administered orally and continuously for 28 days.
Trial: NCT01546038
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine given at 20 mg/m2 over 1 hour infusion for 5-days
Trial: NCT01546038
Drug: PF-04449913
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04449913 administered orally and continuously for 28 days
Trial: NCT01546038
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daunorubicin given using 60 mg/m2 for 3-days
Trial: NCT01546038
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine 100 mg/m2 on days 1 through 7
Trial: NCT01074281
Drug: Enalapril maleate (10 mg) + nitrendipine (20 mg)
RxNorm normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The drug was administered as per the Summary of Product Characteristics (SPC)
Trial: NCT04086342
Drug: CHI-902
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A standardized cannabis extract in MCT oil administered in oral liquid (oil) form.
Trial: NCT00605605
Drug: Dextromethorphan
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 120 mg/day, single once daily dose taken after breakfast by oral route
Trial: NCT02256826
Drug: BILR 355 BS
RxNorm normalized name: BS-001
DrugBank: BS-001 (DB17415)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02256826
Drug: Ritonavir (RTV)
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NORVIR®
Trial: NCT02256826
Drug: Kaletra®
DrugBank: Kale (DB14564)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (lopinavir (LPV) and ritonavir (RTV))
Trial: NCT01546038
Drug: PF-04449913
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04449913 administered orally and continuously for 28 days (if randomized to receive PF-04449913)
Trial: NCT01295567
Drug: Dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: prior to CABG surgery 3 day treatment with dipyridamole 200mg SR twice daily
Trial: NCT02329301
Drug: MDA with DHAp (Eurartesim)
RxNorm normalized name: Primatene with ephedrine Pill
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eurartesim is the brand name.
Trial: NCT00853957
Drug: Aliskiren/Amlodipine
RxNorm normalized name: ALISKIREN/AMLODIPINE
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg
Trial: NCT00853957
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg titrated to 10mg
Trial: NCT04552444
Drug: Biapenem
RxNorm normalized name: biapenem
DrugBank: Biapenem (DB13028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the course of CRKP treatment, double dose biapenem was selected.
Trial: NCT04289090
Drug: Sevoflurane Inhalant Product
RxNorm normalized name: sevoflurane Inhalant Product
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This study will perform intra-operative sonographic ONSD measurements in order to compare the change in ONSD during transition from inhalational maintenance anesthesia (using sevoflurane) to total intravenous anesthesia (TIVA) using propofol.
Trial: NCT04289090
Drug: Propofol 10 MG/ML
RxNorm normalized name: propofol 10 MG/ML
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This study will perform intra-operative sonographic ONSD measurements in order to compare the change in ONSD during transition from inhalational maintenance anesthesia (using sevoflurane) to total intravenous anesthesia (TIVA) using propofol.
Trial: NCT00001300
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02836184
Drug: Nicotinic Acids
RxNorm normalized name: NICOTINIC ACID
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acids is administered at an initial dosage of 50mg four times daily in the first week. If no significant side effects detected, the dosage will be titrated to 100mg five times daily within the second week and last to the end of study.
Trial: NCT02836184
Drug: Calcium Carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium Carbonate 500mg per oral, twice a day
Trial: NCT00001300
Drug: mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04060459
Drug: Paclitaxel-binding albumin
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel-binding albumin 260 mg/m2，d1，ivgtt；cisplatin 75 mg/m2，d1，ivgtt
Trial: NCT03091075
Drug: Oxandrolone
RxNorm normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment group will receive Oxandrolone daily for 12 weeks postoperatively
Trial: NCT00717275
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 75 mg/m2 taken by mouth once a day for 14 out of 28 consecutive days until progression or unacceptable toxicity.
Trial: NCT02635542
Drug: Succinylcholine
RxNorm normalized name: Succinylcholine
DrugBank: Succinylcholine (DB00202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine will be used to facilitate endotracheal intubation for general anesthesia in the operating room. No additional neuromuscular blockade will be provided during general anesthesia.
Trial: NCT02635542
Drug: Cisatracurium
RxNorm normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisatracurium will be used to maintain neuromuscular blockade during general anesthesia.
Trial: NCT01923337
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01923337
Drug: alisertib
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03146871
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV or SC
Trial: NCT03146871
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04016246
Drug: Propofol-Lipuro
RxNorm normalized name: PROPOFOL-LIPURO
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sedation of babies \< 32wGA with propofol / placebo before a LISA Procedure
Trial: NCT00263055
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02508532
Drug: Avapritinib
RxNorm normalized name: Avapritinib
DrugBank: Avapritinib (DB15233)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: avapritinib tablets
Trial: NCT03311425
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Application of 40mg Depomedrol (methylprednisolone acetate) suspension into the retropharyngeal space prior to incision closure
Trial: NCT03311425
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administration of 10mg Dexamethasone IV intraoperatively
Trial: NCT03444298
Drug: Gamma Tocopherol
RxNorm normalized name: Gamma tocopherol
DrugBank: Tocopherol (DB11251)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each dose consists of two (700 mg) capsules by mouth once daily for a total of 7 days.
Trial: NCT00432315
Drug: Docetaxel + CDDP
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * 3 cycles chemotherapy : docetaxel + CDDP~* Surgery (if no histologically proven R0-resection could be achieved,additional adjuvant radiotherapy should be considered)~* 3 cycles adjuvant chemotherapy docetaxel
Trial: NCT00432315
Drug: docetaxel + CDDP
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * 3 cycles chemotherapy: docetaxel + CDDP~* Radiochemotherapy~* 3 cycles adjuvant chemotherapy docetaxel
Trial: NCT00030420
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days
Trial: NCT00231309
Drug: Granulocyte Colony Stimulating Factor
RxNorm normalized name: Granulocyte colony stimulating factor
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Granulocyte Colony Stimulating Factor
Trial: NCT00001569
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001569
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes